InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
15 janv. 2025 12h30 HE
|
InflaRx N.V.
JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced...
RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals
09 janv. 2025 05h00 HE
|
RQ Biotechnology
RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals
HealthSafety Qualified Adapts to New Reality With “Just Ask – Will Mask”
30 déc. 2024 13h00 HE
|
American Ratings Corporation
Petaluma, CA, Dec. 30, 2024 (GLOBE NEWSWIRE) -- American Ratings Corporation (ARC), creator of Diamond Certified Resource, has announced the relaunch of its HealthSafety Qualified Resource website....
ThinkCareBelieve: The Hunter Biden Pardon and US Biolabs in Ukraine
03 déc. 2024 13h17 HE
|
ThinkCareBelieve
Washington, DC, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Link to ThinkCareBelieve's Article: https://thinkcarebelieve.blog/2024/12/02/the-hunter-biden-pardon-and-us-biolabs-in-ukraine/ ThinkCareBelieve...
New U.S. Department of Health and Human Services Campaign Joins HBCU Tour to Increase Flu, COVID-19 Vaccinations
10 sept. 2024 12h21 HE
|
Risk Less. Do More. Pan Respiratory Virus Public Education Campaign
Milwaukee, Wis., Sept. 10, 2024 (GLOBE NEWSWIRE) -- The U.S. Department of Health and Human Services’ (HHS) Risk Less. Do More. campaign is partnering with the HBCU Tailgate Tour to increase...
Politicized Medicine Hindered Use of Ivermectin for COVID, according to the Journal of American Physicians and Surgeons
04 sept. 2024 11h12 HE
|
Association of American Physicians and Surgeons
The politicized response to Covid included a war on the use of ivermectin. Studies have conflicting results. The issue is at a stalemate.
AB Science annonce des résultats positifs de son étude de Phase 2 évaluant le masitinib dans la Covid-19
08 juil. 2024 01h56 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE DES RESULTATS POSITIFS DE SON ETUDE DE PHASE 2 EVALUANT LE MASITINIB DANS LA COVID-19 Paris, 8 juillet 2024, 8h AB Science SA (Euronext - FR0010557264 - AB)...
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
08 juil. 2024 01h56 HE
|
AB Science
PRESS RELEASE AB SCIENCE REPORTS POSTIVE RESULTS OF ITS PHASE 2 STUDY EVALUATING MASITINIB IN COVID-19 Paris, 8 July 2024, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announces the...
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
10 juin 2024 07h30 HE
|
Revive Therapeutics Ltd.
TORONTO, June 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Dyadic to Attend Industry Events in June
30 mai 2024 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...